382 results on '"Gockerman, Jon P."'
Search Results
2. Supplemental Figure 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
3. Supplemental Table 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
4. Supplemental Table 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
5. Supplementary Data from A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia
6. Supplemental Table 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
7. Supplemental Figure 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
8. Supplemental Figure 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
9. Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
10. Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML
11. Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)
12. “Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma
13. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
14. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
15. CLL cell apoptosis induced by nitric oxide synthase inhibitors: Correlation with lipid solubility and NOS1 dissociation constant
16. Chronic lymphocytic leukemia cell CD38 expression and inducible nitric oxide synthase expression are associated with serum IL-4 levels
17. Acute leukemia following treatment of malignant glioma
18. Oligoclonal TRBV gene usage among CD8+ T cells in monoclonal B lymphocytosis and CLL
19. Outcomes of patients who undergo aggresive induction therapy for secondary acute myeloid leukemia
20. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia
21. Aplastic anaemia as an autoimmune complication of thymoma
22. Primary central nervous system lymphoma with systemic metastasis: Case report and review
23. Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkinʼs Disease: Cure Balanced Against Complications
24. Phase III Randomized Trial of Patient-Specific Vaccination for Previously Untreated Patients with Follicular Lymphoma in First Complete Remission: Protocol Summary and Interim Report
25. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
26. Dose-Intense Cyclophosphamide and Etoposide for Patients with Refractory or High-Risk Non-Hodgkinʼs Lymphoma
27. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma
28. Rituximab in Lymphocyte Predominance Hodgkinʼs Disease: A Case Series
29. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma
30. Phase I Evaluation of Prolonged-Infusion Gemcitabine With Irinotecan for Relapsed or Refractory Leukemia or Lymphoma
31. Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study
32. Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed or Refractory Acute Leukemia
33. Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma
34. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B Studies 8852 and 8854
35. A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease
36. The radiographic diagnosis and treatment of paraneoplastic central nervous system disease
37. Fluconazole and Candida krusei Fungemia
38. Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
39. MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC
40. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy
41. Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)
42. Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).
43. Phase I dose escalation and pharmokinetic study of a modified schedule of 14-o-phosphonooxymethyltriptolide.
44. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support: A clinical and pharmacologic study
45. Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial andin vitrostudies
46. Non-Hodgkin’s Lymphomas, Version 1.2013
47. A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma
48. Malignant melanoma presenting as a mediastinal mass
49. Non-Hodgkin’s Lymphomas, Version 3.2012
50. Pilot Study of Sorafenib for Myelodysplastic Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.